They noted that KRASIM is expressed at lower levels in HCC compared to normal hepatocytes and found that it inhibits HCC cell growth and proliferation by reducing KRAS protein levels and dampening ERK signaling pathway activity [70]. Here, NCBP2AS2 is linked to hepatocellular carcinoma.